hardware and software for the development of devices (ResMed Inc)
90
Structured Review
ResMed Inc
hardware and software for the development of devices
Hardware And Software For The Development Of Devices, supplied by ResMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/device+software+development/hardware+and+software+for+the+development+of+devices/pm29425575-145-8-17
Average 90 stars, based on 1 article reviews
Hardware And Software For The Development Of Devices, supplied by ResMed Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/device+software+development/hardware+and+software+for+the+development+of+devices/pm29425575-145-8-17
Average 90 stars, based on 1 article reviews
hardware and software for the development of devices - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Association of serious adverse events with Cheyne-Stokes respiration characteristics in patients with systolic heart failure and central sleep apnoea: A SERVE-Heart Failure substudy analysis. Article Snippet: H.T. has received consulting fees, grant support and Article Title: Effect of a patient engagement tool on positive airway pressure adherence: analysis of a German healthcare provider database. Article Snippet: HT has received consulting fees, grant support, and Article Title: Adaptive servo-ventilation for central sleep apnoea in systolic heart failure: results of the major substudy of SERVE-HF. Article Snippet: H.T. receiving consulting fees, grant support, and Article Title: Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis Article Snippet: Background A large randomised treatment trial (SERVE-HF) showed that treatment of central sleep apnoea with adaptive servoventilation in patients with heart failure and reduced ejection fraction (HFREF) increased mortality, although the analysis of the composite primary endpoint (time to fi rst event of death from any cause, life-saving cardiovascular intervention, or unplanned hospital admission for worsening heart failure) was neutral.. This secondary multistate modelling analysis of SERVE-HF data investigated associations between adaptive servoventilation and individual components of the primary endpoint to try to better understand the mechanisms underlying the observed increased mortality. |